Pluristem Therapeutics (PSTI) receives FDA orphan status for aplastic anemia treatment
- Analog Devices (ADI) to Acquire Linear Technology (LLTC) for ~$60/Share
- Wall St. dips, earnings on deck from Apple and Twitter
- Unusual 11 Mid-Day Movers 7/26: (KOOL) (ALIM) (SPHS) Higher; (TKAI) (CRME) (SDLP) Lower
- Is Apple (AAPL) Finally a Buy Ahead of Q3 Print?
- Netflix (NFLX) Director Jay Hoag Scoops Up 600,000 Shares
Pluristem Therapeutics, Inc. (NASDAQ: PSTI) has received FDA orphan status for aplastic anemia treatment.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Can-Fite BioPharma (CANF) Completes Phase II Protocol Design for CF102 Study in NASH/NAFLD
- Alnylam Pharma (ALNY) Announces Positive Fitusiran Phase 1 Data as Hemophilia and Rare Bleeding Disorders Treatment
- BioTelemetry's (BEAT) MCOT Patch Approved by U.S. FDA